DoW Breast Cancer, Breakthrough Award Levels 1 and 2
Open Posted
- Opportunity number
- HT942526BCRPBTA122
- Agency
-
Medical Command
Department of the Army, Department of Defense
- Applications due
- Award size
- Not on record
Opportunity facts
- Assistance listings
- Funding instrument
- Grant
- Category
-
- Science and Technology and other Research and Development
- Eligible applicants
-
- Unrestricted
- Points of contact
-
- eBRAP Help Desk help@ebrap.org (301) 682-5507
Opportunity details come from Grants.gov. Updated .
About this opportunity
The Department of the Army Medical Command is seeking applications for the fiscal year 2026 Breast Cancer Research Program Breakthrough Award Levels 1 and 2, with a full application deadline of November 18, 2026 and a pre-application deadline of November 4, 2026.
Applicant types are unrestricted; eligible organizations include foreign and domestic entities, for-profit and nonprofit organizations, extramural and intramural Department of War entities. Principal investigators may be postdoctoral fellows, and applications may include two partnering PIs (Initiating PI and Partnering PI) with equal intellectual contribution; failure to submit all associated applications by the deadline may result in administrative withdrawal.
All applications must address at least one of nine overarching FY26 BCRP challenges related to breast cancer prevention, detection, treatment, and metastasis prevention or provide adequate justification for exception. Applications must demonstrate potential to lead to a breakthrough with major impact. Funding Level 1 supports high-risk/high-reward research in early-stage idea development without requiring preliminary data. Funding Level 2 requires substantial preliminary or published data demonstrating feasibility and clinical translation potential and includes a Population Science Studies option that may request higher funding and an additional year in the period of performance with compelling justification. Clinical research is permitted, but clinical trials are not allowed.
The CDMRP expects to allot approximately $10.6 million to fund roughly six awards. Total cost caps are $750,000 (single PI) or $1.25 million (Partnering PI Option) for Level 1; $1.65 million (single PI) or $2.5 million (PPIO) for Level 2; and $2.5 million (single PI) or $3.35 million (PPIO) for Level 2 Population Science Studies. The maximum period of performance is three years for Levels 1 and 2, and four years for Level 2 Population Science Studies. Project narratives are 7 pages for Level 1 and 14 pages for Levels 2. Applications undergo a two-tier review process evaluating technical merit and programmatic relevance. CFDA 12.420 (Military Medical Research and Development).
Synopsis
Summary: The fiscal year 2026 (FY26) Breast Cancer Research Program (BCRP) Breakthrough Award mechanism supports promising research with high potential to lead to or make breakthroughs in breast cancer. All applications must address at least one of the FY26 BCRP overarching challenges or provide adequate justification for exception. Applications must address the challenge in a way that can lead to a breakthrough and have major impact. The FY26 Breakthrough Award mechanism contains four different funding levels designed to support major (but not all) stages of research that will lead to clinical application. Each level specifies a distinct research scope. This program announcement discusses the Breakthrough Award Levels 1 and 2.
Distinctive Features:
* This funding mechanism allows for applications submitted under Funding Level 1 or Funding Level 2. Funding Level 2 also includes a Population Science Studies option. With compelling justification, population science studies may request higher levels of funding and an additional year in the period of performance.
* This funding mechanism allows for a single Principal Investigator (PI), or two partnering PIs referred to as the Initiating PI and the Partnering PI. For the Partnering PI Option (PPIO), only the Initiating PI will submit a pre-application, but both PIs will need to submit at the full application stage. Be advised, failure to submit all associated (Initiating and Partnering PI) applications by the deadline may result in administrative withdrawal.
Files
| File | Type | Posted |
|---|---|---|
| PKG00294130.pdf | ||
| HT942526BCRPBTA122_GG.pdf |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar grant opportunities
- Ask GovTribe AI about this opportunity